GAO Report Examines FDA’s Foreign Drug Inspection Program Amid COVID-19

Government Accountability Office: Drug Safety: COVID-19 Complicates Already Challenged FDA Foreign Inspection Program
“The outbreak of COVID-19 has called greater attention to the United States’ reliance on foreign drug manufacturers. Much of the drug manufacturing for the U.S. market happens overseas — and drugs for treating COVID-19 are no exception. Food and Drug Administration inspections of foreign and domestic drug manufacturers are critical to ensuring drug safety and effectiveness. But FDA began to postpone almost all inspections of foreign manufacturing establishments in March 2020 due to COVID-19. We testified that this lack of foreign inspections removes a critical source of information about the quality of drugs manufactured for the U.S. market…” (6/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.